Related references
Note: Only part of the references are listed.Rational Design for Nitroreductase (NTR)-Responsive Proteolysis Targeting Chimeras (PROTACs) Selectively Targeting Tumor Tissues
Shi Shi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
PROTAC targeted protein degraders: the past is prologue
Miklos Bekes et al.
NATURE REVIEWS DRUG DISCOVERY (2022)
Profiling of diverse tumor types establishes the broad utility of VHL-based ProTaCs and triages candidate ubiquitin ligases
Xin Luo et al.
ISCIENCE (2022)
The Rise of Molecular Glues
Stuart L. Schreiber
CELL (2021)
Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity
Satomi Imaide et al.
NATURE CHEMICAL BIOLOGY (2021)
The HIF-1α antisense long non-coding RNA drives a positive feedback loop of HIF-1α mediated transactivation and glycolysis
Fang Zheng et al.
NATURE COMMUNICATIONS (2021)
Reimagining Druggability Using Chemoproteomic Platforms
Jessica N. Spradlin et al.
ACCOUNTS OF CHEMICAL RESEARCH (2021)
Vascular normalisation as the stepping stone into tumour microenvironment transformation
Anette L. Magnussen et al.
BRITISH JOURNAL OF CANCER (2021)
Cancer Selective Target Degradation by Folate-Caged PROTACs
Jing Liu et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2021)
Aptamer-PROTAC Conjugates (APCs) for Tumor-Specific Targeting in Breast Cancer
Shipeng He et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2021)
Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP
Mengzhu Zheng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Unraveling the Role of Linker Design in Proteolysis Targeting Chimeras
Troy A. Bemis et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Harnessing the E3 Ligase KEAP1 for Targeted Protein Degradation
Jieli Wei et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2021)
Therapeutic targeting of the hypoxic tumour microenvironment
Dean C. Singleton et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Advancing targeted protein degradation for cancer therapy
Brandon Dale et al.
NATURE REVIEWS CANCER (2021)
Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
George M. Burslem et al.
CELL (2020)
Cellular adaptation to hypoxia through hypoxia inducible factors and beyond
Pearl Lee et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2020)
Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction
Mingzhu Yin et al.
NATURE COMMUNICATIONS (2020)
Efficient Targeted Degradation via Reversible and Irreversible Covalent PROTACs
Ronen Gabizon et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2020)
BET protein inhibitor JQ1 downregulates chromatin accessibility and suppresses metastasis of gastric cancer via inactivating RUNX2/NID1 signaling
Siqi Zhou et al.
ONCOGENESIS (2020)
Unifying principles of bifunctional, proximity-inducing small molecules
Christopher J. Gerry et al.
NATURE CHEMICAL BIOLOGY (2020)
Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry
Wen-Hao Guo et al.
NATURE COMMUNICATIONS (2020)
Photoactive Bifunctional Degraders: Precision Tools To Regulate Protein Stability
Cyrille S. Kounde et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Reversible Spatiotemporal Control of Induced Protein Degradation by Bistable PhotoPROTACs
Patrick Pfaff et al.
ACS CENTRAL SCIENCE (2019)
Light-Induced Protein Degradation with Photocaged PROTACs
Gang Xue et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2019)
Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase
Blake E. Smith et al.
NATURE COMMUNICATIONS (2019)
ZMYND8 acetylation mediates HIF-dependent breast cancer progression and metastasis
Yan Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression
Chong Qin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Delineating the role of cooperativity in the design of potent PROTACs for BTK
Adelajda Zorba et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4
Francesca Zanconato et al.
NATURE MEDICINE (2018)
Role of HIF-1 in Cancer Progression: Novel Insights. A Review
Aldo Pezzuto et al.
CURRENT MOLECULAR MEDICINE (2018)
The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer
L. L. da Motta et al.
ONCOGENE (2017)
BET inhibitors: a novel epigenetic approach
D. B. Doroshow et al.
ANNALS OF ONCOLOGY (2017)
Multidimensional Screening Platform for Simultaneously Targeting Oncogenic KRAS and Hypoxia-Inducible Factors Pathways in Colorectal Cancer
Michelle S. Bousquet et al.
ACS CHEMICAL BIOLOGY (2016)
Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras
Honorine Lebraud et al.
ACS CENTRAL SCIENCE (2016)
Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
Michael Zengerle et al.
ACS CHEMICAL BIOLOGY (2015)
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Jing Lu et al.
CHEMISTRY & BIOLOGY (2015)
Ultrasensitive Near-Infrared Fluorescence-Enhanced Probe for in Vivo Nitroreductase Imaging
Yuhao Li et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2015)
BET inhibitor resistance emerges from leukaemia stem cells
Chun Yew Fong et al.
NATURE (2015)
Catalytic in vivo protein knockdown by small-molecule PROTACs
Daniel P. Bondeson et al.
NATURE CHEMICAL BIOLOGY (2015)
Phthalimide conjugation as a strategy for in vivo target protein degradation
Georg E. Winter et al.
SCIENCE (2015)
The bromodomain: From epigenome reader to druggable target
Roberto Sanchez et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2014)
Structure-Guided Design and Optimization of Small Molecules Targeting the Protein Protein Interaction between the von Hippel- Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar Affinities
Carles Galdeano et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
Junwei Shi et al.
MOLECULAR CELL (2014)
BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones
Tomohiko Kanno et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2014)
Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment
Pallavi Chaturvedi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
HIF1A Employs CDK8-Mediator to Stimulate RNAPII Elongation in Response to Hypoxia
Matthew D. Galbraith et al.
CELL (2013)
A Comprehensive Mathematical Model for Three-Body Binding Equilibria
Eugene F. Douglass et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2013)
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Johannes Zuber et al.
NATURE (2011)
Targeting hypoxia in cancer therapy
William R. Wilson et al.
NATURE REVIEWS CANCER (2011)
Hypoxia-Inducible Factors and the Response to Hypoxic Stress
Amar J. Majmundar et al.
MOLECULAR CELL (2010)
Selective inhibition of BET bromodomains
Panagis Filippakopoulos et al.
NATURE (2010)
A biocompatible condensation reaction for controlled assembly of nanostructures in living cells
Gaolin Liang et al.
NATURE CHEMISTRY (2010)
Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization
KangAe Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Brd4 associates with mitotic chromosomes throughout early zebrafish embryogenesis
Reiko Toyama et al.
DEVELOPMENTAL DYNAMICS (2008)
Bromodomain 4 activation predicts breast cancer survival
Nigel P. S. Crawford et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Hypoxia-driven selection of the metastatic phenotype
Richard Sullivan et al.
CANCER AND METASTASIS REVIEWS (2007)
Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis
JA Haapasalo et al.
CLINICAL CANCER RESEARCH (2006)
The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription
MK Jang et al.
MOLECULAR CELL (2005)
Exploiting tumour hypoxia in cancer treatment
JM Brown et al.
NATURE REVIEWS CANCER (2004)
Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation
KM Sakamoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
